跳至主要内容
临床试验/NCT05890599
NCT05890599招募中不适用

Randomized Multicenter Clinical Trial: Yoga Versus Health Education for the Treatment of Persistent Fatigue in Patients With Post COVID-19 Syndrome

University Hospital Tuebingen2 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2023年6月10日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
100
试验地点
2
主要终点
Fatigue

研究概览

简要总结

Evaluation of the short- and medium-term effect of a yoga intervention in addition to routine care compared to health education in addition to routine care on fatigue in patients with post covid syndrome.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Confirmed COVID-19 diagnosis
  • Follow-up symptoms of ≥ 12 weeks
  • Persistent fatigue (scores ≥4 on the binomial Chalder Fatigue Scale).
  • Self-assessment that fatigue was a consequence of COVID-19 disease
  • Age 18-65 years

排除标准

  • Chronic medical conditions or regular use of medications associated with fatigue
  • Indication of health cause of fatigue other than post-COVID.
  • Indication of other factors as the main cause of fatigue
  • Physical limitations that do not allow participation in the yoga intervention
  • Pregnancy, breastfeeding
  • Concurrent participation in other clinical trials
  • Current yoga practice

结局指标

主要结局

Fatigue

时间窗: 12 weeks

The chalder fatigue scale is used to assess the severity of fatigue within the last 4 weeks. It contains 11 questions in a four-step answer format (0-4), 7 of which refer to the degree of physical fatigue and 4 to the degree of mental fatigue. In its binomial evaluation (range 0-11) it can be used with a cut-off of (≥ 4) to divide patients into those with and those without fatigue.

次要结局

  • Fatigue(24 weeks)
  • Health related quality of life SF-12(24 weeks)
  • Movement tracking(24 weeks)
  • Health related quality of life EQ-5D-5L(24 weeks)
  • Psychological symptoms(24 weeks)
  • Sleep quality(24 weeks)
  • Stress(24 weeks)
  • Post-exertional malaise(24 weeks)
  • Body awareness(24 weeks)
  • Self-Efficacy(24 weeks)
  • Adverse events(Week 0, 1-12, 13 and 25)
  • C-reactive proteine(24 weeks)
  • Interleukine-6(24 weeks)
  • D-dimer(24 weeks)
  • Lactate dehydrogenase(24 weeks)
  • Leukocytes and lymphocytes(24 weeks)
  • Hand grip strength(24 weeks)
  • Heart rate variability(24 weeks)
  • Cost for Patient Questionnaire (CoPaQ)(12 weeks, 24 weeks)
  • Lactate dehydrogenase(24 weeks)
  • Leukocytes and lymphocytes(24 weeks)
  • Movement tracking(24 weeks)
  • Fatigue(24 weeks)
  • Health related quality of life SF-12(24 weeks)
  • Health related quality of life EQ-5D-5L(24 weeks)
  • Psychological symptoms(24 weeks)
  • Sleep quality(24 weeks)
  • Stress(24 weeks)
  • Post-exertional malaise(24 weeks)
  • Self-Efficacy(24 weeks)
  • Interleukine-6(24 weeks)
  • D-dimer(24 weeks)
  • Heart rate variability(24 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验